VIRAGE 随机 2b 期试验:静脉注射表达透明质酸酶的溶瘤腺病毒 VCN-01 联合化疗用于转移性胰腺癌
Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial
随机 2b 期 VIRAGE 试验在初治转移性胰腺癌患者中,将静脉注射表达透明质酸酶的溶瘤腺病毒 zabilugene almadenorepvec(VCN-01)联合吉西他滨与白蛋白结合型紫杉醇(GnP)和单用 GnP 进行比较,结果显示 VCN-01 联合 GnP 延长了总生存。该结果发表于 Nature Medicine,原文未披露具体生存数据。
随机 2b 期 VIRAGE 试验比较 VCN-01 联合化疗与单纯化疗在初治转移性胰腺癌中的总生存,可了解该联合方案的研究阶段与设计。
Nature Medicine, Published online: 30 September 2026; doi:10.1038/s41591-026-04705-y
In the randomized phase 2b VIRAGE trial, patients with treatment-naive metastatic pancreatic cancer received the hyaluronidase-expressing oncolytic adenovirus zabilugene almadenorepvec (VCN-01) intravenously with gemcitabine and nab-paclitaxel (GnP) or GnP alone, showing that VCN-01 plus GnP led to prolonged overall survival.
来源:Nature Medicine · nature.com